Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
Timothy Brighton, Amit Khot, Simon J. Harrison, David Ghez, Brendan M. Weiss, A. Kirsch, Hila Magen, Mercedes Gironella, Albert Oriol, Matthew Streetly, Britte Kranenburg, Xiang Qin, Rajesh Bandekar, Peter Hu, Mary Guilfoyle, Ming Qi, Sepideh Nemat, Hartmut Goldschmidt (2019). Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma. , 25(13), DOI: https://doi.org/10.1158/1078-0432.ccr-18-3470.
Article318 days agoMM-691: Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM)
Meletios A Dimopoulos, Peter W. Voorhees, F. Hellem Schjesvold, Yaël C. Cohen, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksac, Keith Stockerl‐Goldstein, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Sara Galimberti, Katarina Uttervall, Bartosz Puła, Eva Medvedova, Andrew J. Cowan, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Annelore Cortoos, Eva G. Katz, Els Rousseau, Liang Li, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar (2025). MM-691: Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM). , 25, DOI: https://doi.org/10.1016/s2152-2650(25)02630-8.
Article63 days agoPOSTER: MM-691 Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM)
Meletios A Dimopoulos, Peter W. Voorhees, F. Hellem Schjesvold, Yaël C. Cohen, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksac, Keith Stockerl‐Goldstein, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Sara Galimberti, Katarina Uttervall, Bartosz Puła, Eva Medvedova, Andrew J. Cowan, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Annelore Cortoos, Eva G. Katz, Els Rousseau, Liang Li, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar (2025). POSTER: MM-691 Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM). , 25, DOI: https://doi.org/10.1016/s2152-2650(25)01280-7.
Article63 days agoPositron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis.
Elena Zamagni, Thierry Façon, Meletios A Dimopoulos, Xavier P. Leleu, Meral Beksaç, Luděk Pour, Roman Hájek, Zhuogang Liu, Jiří Minařík, Philippe Moreau, Joanna Romejko‐Jarosińska, Ivan Spicka, Tom Martin, Lugui Qiu, Christos Sachpekidis, Ercem Kodas, Helgi van de Velde, Liang Zhao, Robert Orlowski, Hartmut Goldschmidt (2025). Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7551.
Article63 days agoDaratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age
Peter M. Voorhees, Meletios A Dimopoulos, Yaël C. Cohen, Fredrik Schjesvold, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksaç, Keith Stockerl‐Goldstein, Hila Magen, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Simon Hallam, Sara Galimberti, Katarina Uttervall, Bartosz Puła, Abdullah Khan, Eva Medvedova, J Christine Ye, Andrew J. Cowan, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Diego Vieyra, Abid Raval, Linlin Sha, Liang Li, Els Rousseau, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar (2025). Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-372.
Article63 days ago